Baseline Characteristics & Outcomes of ASyS and dcSSc Patients Treated with Blinatumomab/Teclistamab & RTX

For patients battling severe autoimmune diseases—specifically anti-Jo1+ antisynthetase syndrome (ASyS) and diffuse cutaneous systemic sclerosis (dcSSc)—conventional treatments often fall short. A recent approach, detailed in a compassionate use programme at the University Hospital of Düsseldorf, explores the potential of targeted therapies, blinatumomab and teclistamab, alongside maintenance rituximab (RTX), for these critically ill individuals.

A Last Resort for Refractory Illness

Understanding the Patient Cohort

The treatment programme involved ten patients—five with ASyS and five with dcSSc—all of whom had exhausted standard treatment options. Every patient with ASyS had previously failed to respond to at least four immunomodulatory medications, including RTX. Similarly, all patients with dcSSc had not responded to at least three different immunomodulatory/antifibrotic drugs. The interventions were conducted under strict ethical guidelines, adhering to the Declaration of Helsinki and receiving approval from the institutional review board (licenses 2022-2189 and 2023-2561).

The Challenges of ASyS

Patients diagnosed with ASyS, characterized by the presence of anti-Jo1 autoantibodies, presented with a range of debilitating symptoms. These included muscle weakness, mechanic’s hands, dyspnea, and, in some cases, interstitial lung disease (ILD). One 65-year-old woman, diagnosed in 2022, had a prior hepatitis B infection and experienced flares requiring multiple courses of prednisolone despite prior treatment with methotrexate, azathioprine, high-dose IVIG, and RTX. Another patient, a 36-year-old man, developed both ILD and myocardial involvement after RTX treatment, requiring multiple interventions including cyclophosphamide, MMF, tacrolimus, and tofacitinib.

The Complexities of dcSSc

The five patients with dcSSc all exhibited widespread skin fibrosis, ILD, and heart involvement. A 65-year-old man, diagnosed in 2006, had progressive ILD despite treatment with cyclophosphamide, azathioprine, and MMF. Another patient, a 46-year-old man, experienced a rapid decline in lung function and new onset of biventricular systolic dysfunction. A common thread among these patients was significant weight loss, with some losing up to 18 kg since their diagnosis.

Did You Know? Blinatumomab is designed to rapidly deplete B cells, with 50% reduction observed after the first hour of infusion and 90% after 4 hours.

A Novel Treatment Approach

recognising the limited efficacy of conventional therapies, researchers offered blinatumomab or teclistamab through a compassionate use programme. Prior to initiating these treatments, all patients discontinued other immunomodulatory and antifibrotic drugs for at least one week. Blinatumomab, administered via continuous intravenous infusion, and teclistamab, given subcutaneously, were employed with specific premedication protocols to manage potential side effects.

Maintaining Remission with Rituximab

To prevent the re-emergence of autoantibody-producing B cells, rituximab (RTX) was administered following the initial course of blinatumomab or teclistamab. The RTX dosing schedule was individualized, considering the patient’s response and the pharmacokinetics of the prior treatment. In patients with SSc, RTX was initiated two weeks after the final teclistamab dose, demonstrating complete suppression of peripheral B cell counts and a decline in autoantibodies.

Expert Insight: The use of compassionate use programmes highlights the critical need for innovative treatment options when patients have exhausted all standard therapies. This approach allows for the exploration of potentially life-saving interventions in carefully selected cases, while acknowledging the inherent uncertainties of experimental treatments.

Looking Ahead

While this programme represents a significant step in addressing these challenging conditions, further research is needed to fully evaluate the long-term efficacy and safety of blinatumomab, teclistamab, and RTX in combination. Continued monitoring of these patients will reveal more about the optimal dosing schedules and potential biomarkers for treatment response. A larger, controlled clinical trial could help to confirm these initial findings and establish a new standard of care for ASyS, and dcSSc.

Frequently Asked Questions

What is a compassionate use programme?

A compassionate use programme allows access to experimental treatments for patients with serious or life-threatening conditions when standard therapies have failed, as outlined in the Arzneimittelgesetz Section 21/2 and the Arzneimittel-Härtefall-Verordnung Section 2.

What are anti-Jo1 autoantibodies?

Anti-Jo1 autoantibodies are present in all patients with ASyS included in this study and are a defining characteristic of the condition.

What is dcSSc?

dcSSc stands for diffuse cutaneous systemic sclerosis, a form of scleroderma characterized by widespread skin thickening and internal organ involvement.

Given the complexities of autoimmune diseases like ASyS and dcSSc, what role do you think personalized medicine will play in tailoring treatments to individual patient needs?